Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Neovacs S.A.

Eligo Bioscience is a biotechnology company focused on the development of innovative microbiome therapies. The company leverages cutting-edge technology to engineer beneficial microbes that can specifically target and eliminate harmful bacteria, aiming to treat a range of diseases linked to the human microbiome.

David Bikard

Timothy K. Lu

Xavier Duportet

Luciano Marraffini

Eligo Bioscience

Aixial Group is a Clinical Research Organisation that collaborates with sponsors to develop therapies for oncology, cell & gene therapy, and rare diseases. It provides various clinical trial services and consulting.

Aixial Group

Amolyt Pharma is a biopharmaceutical company focused on developing treatments for hypoparathyroidism, a rare endocrine disorder. The company is developing eneboparatide, a novel parathyroid hormone receptor 1 (PTHR1) agonist, which has demonstrated promising results in clinical trials.

Thierry Abribat

Amolyt Pharma

Néovacs is a French biotechnology company that develops products and invests in innovative companies in Biotech and Medtech. It has distinct activities in Research and Development and investment.

Metric
Company Name	Neovacs S.A.	Eligo Bioscience	Aixial Group	Amolyt Pharma
Symbol	ALNEV
MSH ID	COM:NEOVACS	BIO:ELIGO	COM:AIXIALGROUP	COM:AMOLYTPHARMA
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	8
Industry	Biotechnology	Biotechnology	Clinical Research	Healthcare & Health Services
Country	FR	FR	FR	FR
Stage	Post-IPO Debt			Series
Employee Count	22	42		61
Website	neovacs.com	eligo.bio	aixialgroup.com	amolytpharma.com
LinkedIn	neovacs	eligo-bioscience	aixialgroup	amolytpharma
Founders

Metric
Market Cap	52.99K
Enterprise Value
Monthly Web Traffic		539
Web Traffic Growth		-0.86
Valuation
Raised Capital	4.77M	138.63M

Metric
Revenue	563.41K
Revenue (LTM)
Revenue (NTM)
Gross Profit	-7.13M
EBITDA	-7.12M
Operating Income	-7.30M
Net Income	-9.24M
EPS	-0.00
Diluted EPS	-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-9.71
Operating Profit Margin	-12.95
EBITDA Margin	-12.64
Net Profit Margin	-16.39
Return on Equity	-0.12
Return on Assets	-0.11
Return on Capital Employed	-0.14

COM:NEOVACS

Néovacs

Last Close

0.00

25/11 08:00

Market Cap

50.16K

Beta: -

Volume Today

9.50M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.78
EV Multiple	-0.04

Metric
Days Sales Outstanding
Days Payables Outstanding	1.22K
Days Inventory Outstanding
Operating Cycle	11.67K
Cash Conversion Cycle	11.39K
Asset Turnover	0.01

Metric
Operating Cash Flow	-2.02M
Free Cash Flow	-2.24M
Cash Flow to Debt	-1.47
Operating Cash Flow/Sales	-3.59
Free Cash Flow Yield	-0.00

Metric
Cash & Equivalents	936.97K
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization	0.06
Debt to Assets	0.02
Current Ratio	2.32
Quick Ratio	1.34

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue